David Heilman

Title: The Innovations of David Heilman

Introduction

David Heilman is an accomplished inventor based in Hillsborough, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of HIV. His innovative work has led to the development of a unique pharmaceutical composition that enhances the administration of HIV gp41-derived peptides.

Latest Patents

David Heilman holds a patent for a pharmaceutical composition aimed at improving the administration of HIV gp41-derived peptides. This patent describes a solution that includes a synthetic peptide in a concentration of not less than 70 mg/ml, combined with a polyol. The synthetic peptide acts as an HIV fusion inhibitor, while the polyol is present in a concentration ranging from 5 weight % to 75 weight % of the overall composition. Additionally, the patent outlines a method for treating HIV infection by administering this innovative pharmaceutical composition to individuals infected with the virus.

Career Highlights

Heilman is associated with Trimeris, Inc., a company known for its focus on developing therapies for viral infections. His work at Trimeris has been pivotal in advancing treatment options for HIV patients. With a patent portfolio that includes this significant innovation, Heilman has established himself as a key figure in pharmaceutical research.

Collaborations

Throughout his career, David Heilman has collaborated with notable colleagues, including Jie Di and Brian L Bray. These partnerships have contributed to the success of his research and the development of effective therapeutic solutions.

Conclusion

David Heilman's contributions to the field of pharmaceuticals, particularly in HIV treatment, highlight his innovative spirit and dedication to improving patient care. His patent for a pharmaceutical composition represents a significant advancement in the administration of HIV therapies.